Oncology News

The combination of atezolizumab and bevacizumab prolonged survival compared with standard-of-care sorafenib for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy, according to topline data from the phase 3 IMbrave150 study.

Patients who developed hepatitis C-related hepatocellular carcinoma after achieving sustained virologic response with interferon-free direct-acting antivirals had a 60% to 70% improvement in 5-year survival compared with untreated patients.

CHICAGO — During this year’s North American Society for Pediatric Gastroenterology, Hepatology & Nutrition annual meeting, Mercedes Martinez, MD, from the New York-Presbyterian Columbia University Irving Medical Center in New York, will co-host the Single Topic Symposium on Chronic Liver Disease Management for the Gastroenterologist.

In contrast to previous study results, hepatocellular carcinoma and decompensated cirrhosis rates were similar between patients coinfected with hepatitis C and HIV and those with hepatitis C alone, according to data.

As liver cancer rates continue to increase globally, researchers have focused on novel treatment options including combination therapies and second-line options for patients with insufficient response to initial therapy.

AVEO Oncology initiated enrollment in an early trial of a combination therapy using Fotivda and Imfinzi for the treatment of hepatocellular carcinoma with no prior systemic therapy, according to a press release.

Incyte announced positive overall response rate and progression-free survival results for pemigatinib, a selective fibroblast growth factor receptor inhibitor under evaluation for patients who failed previous treatment for advanced or metastatic cholangiocarcinoma, according to a press release.

Statin therapy correlated with a reduced risk for hepatocellular carcinoma in patients with chronic hepatitis B, according to results published in Hepatology.

BARCELONA, Spain — Nivolumab did not significantly extend OS compared with sorafenib as first-line therapy for patients with advanced hepatocellular carcinoma, according to results of the randomized phase 3 CheckMate 459 trial presented at European Society for Medical Oncology Congress.

Treatment with Cabometyx as second-line therapy for patients with advanced hepatocellular carcinoma who previously received Nexavar demonstrated superior progression-free survival and improved overall survival compared with Stivarga, according to a study presented at the International Liver Cancer Association 2019 meeting and a press release.